CNB-001
CNB-001 is a potent and orally active 5-lipoxygenase (5-LOX) inhibitor. CNB-001 can decreases 5-LOX expression and increase proteasome activity. CNB-001 can inhibit accumulation of soluble Amyloid-β and ubiquitinated aggregated proteins. CNB-001 can inhibit apoptosis, ROS production and stabilize mitochondrial membrane potential. CNB-001 can reduce insulin resistance and increase glucose uptake. CNB-001 also exhibits anti-ischemic, anti-inflammatory effects. CNB-001 can be used for the researches of inflammation, neurological and metabolic disease, such as Alzheimer's disease, stroke and diabetes[1][2][3][4].
Product Specifications
CAS Number
1019110-87-2
UNSPSC
12352005
Target
Amyloid-β; Apoptosis; Lipoxygenase; Reactive Oxygen Species (ROS)
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB
Applications
Neuroscience-Neurodegeneration
Field of Research
Metabolic Disease; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/cnb-001.html
Purity
90.70
Solubility
10 mM in DMSO
Smiles
OC1=CC=C(C=C1OC)/C=C/C2=NN(C3=CC=CC=C3)C(/C=C/C4=CC(OC)=C(O)C=C4)=C2
Molecular Formula
C27H24N2O4
Molecular Weight
440.49
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
15-LOX;5-LOX
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Prepacked FPLC Columns, Affinity Chromatography
PDHA1 (PHE1A, Pyruvate Dehydrogenase E1 Component Subunit alpha, Somatic Form, Mitochondrial, PDHE1-A Type I)
